Abstract
Healthcare systems today are undergoing major restructuring. From the patient’s perspective, expectations focusing on high quality treatments for most common diseases – such as cancer, cardiovascular diseases, neurodegenerative diseases, diabetes, and others – have gone unmet in most countries throughout the world. Today, a number of protein expression and analysis platforms is available, which can generate large-scale maps of proteins related to healthy and diseased states. These mass spectrometry-based technologies are used on a daily basis by thousands of research laboratories around the world. The major interest is focused on discovery and validation of novel biomarkers in various diseases, as well as on targeted proteomics where quantification of multiple protein biomarkers is achieved. We present these technological developments in relation to disease diagnosis and treatment and provide two examples where significant progress has been made.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aebersold R, Auffray C, Baney E, Barillot E, Brazma A, Brett C, et al. Report on EU-USA workshop: how systems biology can advance cancer research (27 October 2008). Mol Oncol. 2009;3(1):9–17.
Anderson NL. The roles of multiple proteomic platforms in a pipeline for new diagnostics. Mol Cell Proteomics. 2005;4(10):1441–4.
Anderson NL, Anderson NG. The human plasma proteome – history, character, and diagnostic prospects. Mol Cell Proteomics. 2002;1(11):845–67.
Andrejevs G, Celis JE, Guidi G, Peterle A, Sullivan R, Wilson R. Tackling cancer in the EU: the role of innovation. Mol Oncol. 2009;3(1):18–23.
Apweiler R, Aslanidis C, Deufel T, Gerstner A, Hansen J, Hochstrasser D, et al. Approaching clinical proteomics: current state and future fields of application in cellular proteomics. Cytometry A. 2009;75(10):816–32. Epub 2009/09/10.
Cho CR, Labow M, Reinhardt M, van Oostrum J, Peitsch MC. The application of systems biology to drug discovery. Curr Opin Chem Biol. 2006;10(4):294–302. Epub 2006/07/11.
Domanski D, Percy AJ, Yang J, Chambers AG, Hill JS, Freue GVC, et al. MRM-based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma. Proteomics. 2012;12(8):1222–43.
Domon B, Aebersold R. Review – mass spectrometry and protein analysis. Science. 2006;312(5771):212–17.
Kato H, Nishimura T, Hirano T, Nomura M, Tojo H, Fujii K, et al. A clinician view and experience of proteomic studies in the light of lung cancer in Japanese healthcare. J Proteome Res. 2011a;10(1):51–7.
Kato H, Nishimura T, Ikeda N, Yamada T, Kondo T, Saijo N, et al. Developments for a growing Japanese patient population: facilitating new technologies for future health care. J Proteomics. 2011b;74(6):759–64.
Keshishian H, Addona T, Burgess M, Mani DR, Shi X, Kuhn E, et al. Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics. 2009;8(10):2339–49.
Kuhn E, Addona T, Keshishian H, Burgess M, Mani DR, Lee RT, et al. Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem. 2009;55(6):1108–17.
Legrain P, Aebersold R, Archakov A, Bairoch A, Bala K, Beretta L, et al. The human proteome project: current state and future direction. Mol Cell Proteomics. 2011;10(7):M111.009993.
Lilja H, Ulmert D, Bjork T, Becker C, Serio AM, Nilsson JA, et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol. 2007;25(4):431–6.
Mann M. Comparative analysis to guide quality improvements in proteomics. Nat Methods. 2009;6(10):717–19.
Marko-Varga G, Fehniger TE. Proteomics and disease – the challenges for technology and discovery. J Proteome Res. 2004;3(2):167–78.
Marko-Varga GA, Végvári Á, Fehniger TE. A protein shake-up. Public Serv Rev Eur Union. 2011;21:250–2.
Olsen JV, Schwartz JC, Griep-Raming J, Nielsen ML, Damoc E, Denisov E, et al. A dual pressure linear ion trap orbitrap instrument with very high sequencing speed. Mol Cell Proteomics. 2009;8(12):2759–69.
Paavilainen L, Edvinsson A, Asplund A, Hober S, Kampf C, Ponten F, et al. The impact of tissue fixatives on morphology and antibody-based protein profiling in tissues and cells. J Histochem Cytochem. 2010;58(3):237–46. Epub 2009/11/11.
Paik YK, Jeong SK, Omenn GS, Uhlen M, Hanash S, Cho SY, et al. The chromosome-centric human proteome project for cataloging proteins encoded in the genome. Nat Biotechnol. 2012a;30(3):221–3.
Paik YK, Omenn GS, Uhlen M, Hanash S, Marko-Varga G, Aebersold R, et al. Standard guidelines for the chromosome-centric human proteome project. J Proteome Res. 2012b;11(4):2005–13.
Rezeli M, Végvári Á, Fehniger TE, Laurell T, Marko-Varga G. Moving towards high density clinical signature studies with a human proteome catalogue developing multiplexing mass spectrometry assay panels. J Clin Bioinformatics. 2011;1(1):7.
Rinn JL, Rozowsky JS, Laurenzi IJ, Petersen PH, Zou K, Zhong W, et al. Major molecular differences between mammalian sexes are involved in drug metabolism and renal function. Dev Cell. 2004;6(6):791–800.
Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci. 1998;35(4):275–368.
Schmidt A, Claassen M, Aebersold R. Directed mass spectrometry: towards hypothesis-driven proteomics. Curr Opin Chem Biol. 2009;13(5–6):510–17.
Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–8.
Schwenk JM, Gry M, Rimini R, Uhlen M, Nilsson P. Antibody suspension bead arrays within serum proteomics. J Proteome Res. 2008;7(8):3168–79.
Végvári Á, Marko-Varga G. Clinical protein science and bioanalytical mass spectrometry with an emphasis on lung cancer. Chem Rev. 2010;110(5):3278–98.
Végvári Á, Rezeli M, Welinder C, Malm J, Lilja H, Marko-Varga G, et al. Identification of prostate-specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms. J Proteomics. 2010;73(6):1137–47.
Végvári Á, Rezeli M, Sihlbom C, Häkkinen J, Carlsohn E, Malm J, et al. Molecular microheterogeneity of prostate specific antigen in seminal fluid by mass spectrometry. Clin Biochem. 2012;45(4–5):331–8.
Weissenstein U, Schneider MJ, Pawlak M, Cicenas J, Eppenberger-Castori S, Oroszlan P, et al. Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts. Proteomics. 2006;6(5):1427–36.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Végvári, Á., Rezeli, M., Erlinge, D., Marko-Varga, G. (2013). Clinical and Biomedical Mass Spectrometry: New Frontiers in Drug Developments and Diagnosis. In: Wang, X. (eds) Bioinformatics of Human Proteomics. Translational Bioinformatics, vol 3. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-5811-7_7
Download citation
DOI: https://doi.org/10.1007/978-94-007-5811-7_7
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-5810-0
Online ISBN: 978-94-007-5811-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)